LIBERTEX
29.3.2024 06:26:33 CET | Business Wire | Press release
As the first quarter of 2024 draws to a close, Libertex is thrilled to announce its first accolade of the new year! The established global financial publication PAN Finance has determined Libertex to be the ‘CFD Broker of the Year – Global 2024’ following a rigorous evaluation process conducted by the publication's highly experienced editorial and research teams.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328235325/en/
(Graphic: Libertex)
PAN Finance is a trusted source of global financial intelligence with an impressively wide readership across 150 countries. Its ecosystem includes a quarterly magazine, special reports, a news website, and various social media channels. As an organisation, PAN Finance is committed to providing concise, intelligent, and up-to-date news for a worldwide readership of specialists spanning the entire finance industry. The company's awards programme aims to serve as a true indicator of excellence, identifying organisations and individuals that have excelled in their respective fields and shining a spotlight on leading examples of best practices. Previous winners have included titans of the financial services market, such as HSBC, Santander, and Stripe, all of whom have noted the prestige of such an honour.
Speaking on the occasion of this prestigious award, Libertex Group CMO Marios Chailis had the following to say: "It goes without saying that we are always delighted when our hard work is recognised, but when this recognition comes from a respected organisation of the level of PAN Finance, which counts former UN Secretary-General Ban Ki-moon and various former presidents and ministers amongst its many past contributors, the feeling is even more pronounced for us. Everyone at Libertex works tirelessly to ensure our CFD offering and service quality are strong across the board, so it's truly fantastic to be recognised with such an immense honour. It certainly shows we're doing something right! Nonetheless, we are committed to maintaining this high standard throughout the rest of the year and beyond, and I am overly confident that I will be able to report further similar accolades in the coming months."
Libertex is constantly seeking to improve the service it provides. Whether it be by extending its CFD offering to include popular new instruments that traders seek or by partnering with global sports giants such as FC Bayern to create dynamic and exciting synergies, Libertex always tries to give that little bit extra. This approach is directly connected to the company's Trade for More philosophy, which enables Libertex clients to go beyond simple trading. Throughout the rest of 2024 and beyond, Libertex will continue to work hard to provide a CFD trading service worthy of "Broker of the Year".
Find out more about Libertex at https://www.libertex.com (EEA and Switzerland clients) or https://www.libertex.org (non-EEA/Switzerland clients).
More about Libertex
Part of the Libertex Group, Libertex is an online broker offering tradable CFDs with underlying assets such as commodities, stocks, forex, ETFs, cryptocurrencies, and others.
Over the years, Libertex has received multiple prestigious international awards and recognitions, including "CFD Broker of the Year - Global" (PAN Finance Awards, 2024), "Best Trading Experience" (Ultimate Fintech Awards, 2023) and "Best CFD Broker" (World Finance Forex Awards, 2023). Libertex is the Official Online Trading Partner of FC Bayern, in what has become a dynamic and exciting partnership.
Since being founded in 1997, the Libertex Group has grown into a robust fintech powerhouse with an established presence in various jurisdictions, serving millions of clients from several countries all over the world.
In Europe, the Libertex trading platform is operated by Indication Investments Ltd., a Cyprus Investment Firm regulated and supervised by the Cyprus Securities and Exchange Commission (CySEC) with CIF License number 164/12.
In other jurisdictions, the Libertex trading platform is operated by Forex Club International LLC, a company registered in St. Vincent and the Grenadines (Registration No. 1277 LLC 2021) and by MAEX LIMITED, a company registered in the Republic of Mauritius (Registration No. 158250 C1/GBL and Licence № С118023400 issued by the Financial Services Commission, Mauritius).
European Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 73.77% of retail investor accounts lose money when trading CFDs with this provider. Tight spreads apply. Please check our spreads on the platform. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328235325/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
China's ~$900B Live-Commerce Market Now Approaches US E-Commerce Scale17.7.2026 12:30:00 CEST | Press release
The consumer habits reshaping global retail were built in the East — and most Western shoppers haven't yet adopted them. NIQ report shows that brands still treating live, social, and quick commerce as "emerging" risk being left behind. The center of gravity in global retail has shifted East. The formats now driving the fastest growth in global retail (live shopping, social commerce, and delivery in minutes) were pioneered and scaled in Asia, and most Western consumers have yet to adopt them. According to NIQ (NYSE: NIQ), a leading consumer intelligence company, in its global report The Commerce Revolution: Where East Meets West, the gap between East and West is still vast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717253489/en/ China´s USD 900bn live shopping boom now approaches the scale of the US E-commerce The scale is already substantial. China's live-commerce market alone was worth roughly $900 billion in 2025,
Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS,Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 12:17:00 CEST | Press release
Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom